Cargando…
免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973355/ https://www.ncbi.nlm.nih.gov/pubmed/28641702 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10 |